Author name: Dr. Rathod Medical Foundation

Liver cirrhosis is a progressive condition in which healthy liver tissue is gradually replaced by scar tissue, reducing the organ’s ability to function. It develops over several years and often shows no clear signs in its early phases. Because the damage progresses slowly, many patients remain unaware of the condition until it advances. Stage 3 liver cirrhosis represents a critical phase where the scarring becomes severe and the liver begins to struggle with essential functions. At this stage, complications such as fluid accumulation and bleeding risks often start to appear, making timely medical attention important for managing the condition effectively. Dr. Vipulroy Rathod, a highly respected gastroenterologist in Mumbai, India, highlights, “Stage 3 cirrhosis is the phase where complications begin to surface, so close monitoring becomes essential.” He further adds, “While the scarring cannot be reversed, the right treatment approach can slow progression and improve quality of life significantly.”    Dr. Rathod is widely recognized for his expertise in managing complex liver and digestive disorders. With considerable experience in advanced diagnostic and therapeutic procedures, he focuses on controlling complications and preserving liver function for as long as possible. His approach to stage 3 liver cirrhosis centres on early detection of complications, individualised treatment planning, and consistent follow-up, helping patients maintain stability and avoid rapid deterioration. What Causes Stage 3 Liver Cirrhosis? Stage 3 cirrhosis develops when ongoing liver damage continues without adequate treatment. Several underlying conditions contribute to this advanced scarring. Common causes include: Chronic alcohol use: Long-term heavy drinking progressively damages liver cells. Viral hepatitis: Hepatitis B and C infections cause persistent inflammation that leads to scarring. Fatty liver disease: Fat accumulation, often linked to obesity and diabetes, gradually harms the liver. Autoimmune conditions: In some patients, the immune system mistakenly attacks healthy liver tissue. Bile duct disorders: Blockage or injury to the bile ducts can trigger chronic liver damage. Identifying the underlying cause is key to slowing progression and planning effective treatment. How Is PEI Diagnosed and Treated? Diagnosis takes one test. Treatment takes one medication. The problem is neither happens for months because nobody considers the pancreas until everything else has been tried first. Fecal Elastase: Stool sample. Result in 48 hours. Below 200 is moderate. Below 100 is severe. That’s it. One test. Would have saved the patient months of elimination diets, probiotics, and frustration if someone had ordered it at the first appointment. PERT: Enzyme replacement capsules with every meal and snack. Start at 40,000 to 50,000 units lipase per main meal, 25,000 per snack. Most patients feel genuinely different within 2 to 4 weeks. Stools normalise. Bloating drops. Weight starts recovering. They ask why nobody started this sooner. Vitamins: A, D, E, K can’t absorb without lipase. Check levels. Supplement what’s low. Patient comes in with bone pain from D deficiency, bruising from K, fatigue nobody explained. Put those findings next to oily stools and weight loss and the diagnosis writes itself. Cause: PERT fixes the symptom. Doesn’t fix the patient. Chronic pancreatitis needs managing. Cancer needs ruling out. Surgical patients need monitoring. Enzyme capsules without investigating why the pancreas stopped working is like treating a fever without looking for the infection. PEI responds to treatment quickly when diagnosed properly. Read more on enzyme deficiency signs to understand which specific symptoms should trigger testing and how dose titration works in real clinical practice. Noticing unusual symptoms or have a history of liver issues? Connect with a specialist to assess your liver health and next steps. Book Appointment Call now Common Symptoms of Stage 3 Liver Cirrhosis Symptoms become more noticeable at this stage as liver function declines and complications begin to develop. Common symptoms include: Fluid accumulation in the abdomen (ascites), causing swelling and discomfort Jaundice, with yellowing of the skin and eyes Easy bruising and bleeding due to impaired clotting Persistent fatigue and general weakness Swelling in the legs and ankles (edema) Confusion or difficulty concentrating, in some cases “Recognising symptoms such as ascites or jaundice early can prevent complications and ensure better outcomes,” states Dr. Vipulroy Rathod. Liver biopsy Confirms the severity of cirrhosis when required Blood tests Assess liver function, clotting ability, and help identify the underlying cause Ultrasound: Visualises the liver structure and detects fluid accumulation CT scan or MRI Provides detailed imaging of the damage and any complications Together, these tests provide a clear picture of the condition and guide appropriate treatment. Treatment Options for Stage 3 Liver Cirrhosis   Since the scarring cannot be reversed, treatment focuses on slowing progression, managing complications, and addressing the underlying cause. The treatment options include: · Treating the Underlying Cause This may involve antiviral medication for hepatitis or complete cessation of alcohol, both of which help prevent further liver damage. · Managing Fluid Retention Diuretics and a low-salt diet are used to control ascites and swelling, with fluid drainage performed in severe cases. · Controlling Bleeding Risks Medications and endoscopic procedures help manage enlarged varices and reduce the risk of dangerous bleeding. · Nutritional Support A carefully planned diet supports liver function and addresses the malnutrition common at this stage. · Medications for Complications Specific medications are prescribed to manage hepatic encephalopathy and prevent infections. · Regular Monitoring Frequent checkups and screening help detect complications early and track the progression of the condition. · Liver Transplant Evaluation In advanced cases where the liver fails to function adequately, transplant evaluation may be considered as a long-term solution. Early and appropriate treatment significantly improves quality of life and reduces the risk of serious complications. What happens if stage 3 cirrhosis is left untreated? Let’s understand the potential risks. Complications if Stage 3 Cirrhosis is Left Untreated Without proper control, stage 3 liver cirrhosis can worsen and cause fatal outcomes. Complications that can develop include: Complete liver failure with development of stage 4 cirrhosis Internal bleeding due to varices rupturing Severe fluid accumulation in the abdomen and infections Changes in brain function due to hepatic encephalopathy Strong possibility of there being liver cancer Intervening

Pancreatic exocrine insufficiency is what you get when the pancreas can’t make enough enzymes to digest food. Lipase, protease, amylase, all of them drop. Fat goes through unabsorbed, protein follows, and the patient ends up malnourished while eating three meals a day. Chronic pancreatitis causes most cases we see. Cancer, surgery, even long-standing diabetes can do it too. And the frustrating part is how long it takes to diagnose, because the symptoms look identical to IBS on paper and nobody orders a fecal elastase until somebody finally thinks of it. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “PEI is underdiagnosed because the symptoms look like half a dozen other GI conditions and most clinicians don’t test pancreatic function unless they already suspect pancreatic disease, so the patients who need enzyme replacement the most are exactly the ones who wait the longest to get it.” What Causes Pancreatic Exocrine Insufficiency? Several things break the enzyme-producing machinery. Some destroy tissue. Some block delivery. Doesn’t matter how it happens, the gut can’t digest without enzymes. Pancreatitis: Most common cause in adults. Years of inflammation replacing functional acinar cells with scar tissue. Here’s the thing though, by the time PEI symptoms show up clinically, 90% of exocrine function is already gone because the pancreas has enough reserve to mask early damage, so patients feel fine until they suddenly don’t. Cancer: Tumour blocks the main duct or eats into enzyme-producing tissue directly. PEI showing up with weight loss in a patient over 50 should always trigger imaging. Always. Because the enzyme deficiency might be the first clue that something worse is sitting underneath and starting PERT without investigating is incomplete. Surgery: Any operation removing part of the pancreas reduces enzyme output proportionally. Whipple, distal pancreatectomy, total pancreatectomy. Post-surgical PEI is basically guaranteed after major resection. Lifelong replacement from day one, no question about it. Diabetes: This one surprises people. Long-standing Type 2 diabetes is associated with PEI in 30 to 50% of patients in some studies. Most endocrinologists don’t screen for it. Diabetic patient with unexplained bloating, oily stools, weight dropping, gets told to fix their diet when a fecal elastase would have given the answer in two days. Causes overlap in the same patient more often than you’d expect. Specialist in pancreatitis treatment finds out what broke the enzyme production rather than just handing over capsules without asking why. How Is PEI Diagnosed and Treated? Diagnosis takes one test. Treatment takes one medication. The problem is neither happens for months because nobody considers the pancreas until everything else has been tried first. Fecal Elastase: Stool sample. Result in 48 hours. Below 200 is moderate. Below 100 is severe. That’s it. One test. Would have saved the patient months of elimination diets, probiotics, and frustration if someone had ordered it at the first appointment. PERT: Enzyme replacement capsules with every meal and snack. Start at 40,000 to 50,000 units lipase per main meal, 25,000 per snack. Most patients feel genuinely different within 2 to 4 weeks. Stools normalise. Bloating drops. Weight starts recovering. They ask why nobody started this sooner. Vitamins: A, D, E, K can’t absorb without lipase. Check levels. Supplement what’s low. Patient comes in with bone pain from D deficiency, bruising from K, fatigue nobody explained. Put those findings next to oily stools and weight loss and the diagnosis writes itself. Cause: PERT fixes the symptom. Doesn’t fix the patient. Chronic pancreatitis needs managing. Cancer needs ruling out. Surgical patients need monitoring. Enzyme capsules without investigating why the pancreas stopped working is like treating a fever without looking for the infection. PEI responds to treatment quickly when diagnosed properly. Read more on enzyme deficiency signs to understand which specific symptoms should trigger testing and how dose titration works in real clinical practice. Why Choose Dr. Vipulroy Rathod for Pancreatic Exocrine Insufficiency? Dr. Vipulroy Rathod has spent over 30 years diagnosing pancreatic disease at Fortis Hospital Mulund. Caught PEI in patients labelled IBS for years because one fecal elastase test hadn’t been ordered. EUS since 1998 means the underlying cause gets identified in the same workup, not six months later. 35 countries worth of physicians trained in this approach. Patients arrive having tried everything except the right test. Most leave with enzyme replacement working within weeks, a diagnosis for why it happened, and a plan that actually addresses both.   Book your consultation today with one of India’s most experienced specialists for pancreatic exocrine insufficiency diagnosis and treatment. Book Appointment Call now Frequently Asked Questions What is the most common cause of pancreatic exocrine insufficiency? Chronic pancreatitis is the most common cause of PEI in adults, destroying enzyme-producing tissue through repeated inflammation over years. How is PEI diagnosed? Fecal elastase test on a stool sample is the standard non-invasive diagnostic method, with levels below 200 indicating PEI. Is PEI the same as pancreatic enzyme deficiency? Yes, PEI and pancreatic enzyme deficiency describe the same condition where the pancreas fails to produce adequate digestive enzymes. Can PEI be cured permanently? PEI from chronic pancreatitis or surgery is usually permanent and requires lifelong enzyme replacement, while PEI from reversible causes may improve with treatment of the underlying condition. Reference links- Pancreatic Exocrine Insufficiency Diagnosis — American College of Gastroenterology PEI Management Guidelines — World Gastroenterology Organisation

Pancreatic enzyme deficiency, or EPI, is what happens when the pancreas can’t produce enough lipase, protease, and amylase to digest food the way it should. Usually chronic pancreatitis behind it, sometimes cancer, sometimes surgery that took part of the organ out. Fat passes through unabsorbed, protein the same, patient drops weight, stools turn oily and foul, bloating after every meal, and the whole thing gets labelled IBS or food intolerance for months because nobody ordered a fecal elastase. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Pancreatic enzyme deficiency is one of those conditions where patients suffer with digestive symptoms for a long time before anyone thinks to test pancreatic function, and by the time we see them most have already lost significant weight and developed nutritional deficiencies that could have been prevented.” What Are the Signs of Pancreatic Enzyme Deficiency? Looks like IBS on paper. Feels like IBS to the patient. But test the pancreas and the picture changes completely. Steatorrhoea: Oily pale stools that float and won’t flush. Fat malabsorption, plain and simple. Patients describe dealing with this for years while being told it’s dietary, and one fecal elastase test would have given the answer months ago. Weight: Dropping weight despite eating normally or more. Fat and protein passing through unabsorbed no matter how much goes in. Patient gets told to eat better. Nobody measures enzyme output. The gap between what’s eaten and what’s absorbed keeps widening. Bloating: Worse after fatty meals. Undigested fat fermenting in the gut. Gets managed with antacids, probiotics, elimination diets, everything except the one test that would explain it, and meanwhile the malabsorption continues unchecked. Deficiencies: Vitamins A, D, E, K need lipase for absorption. Without it you get bone pain from D deficiency. Easy bruising from K. Fatigue nobody can explain on routine bloods. Connect those back to the pancreas and suddenly the whole picture makes sense. These matter more when there’s pancreatitis history, prior surgery, or diabetes that appeared without obvious metabolic reason. Specialist in pancreatitis treatment tests pancreatic function as part of the workup rather than chasing individual symptoms separately. How Is Pancreatic Enzyme Deficiency Treated? Diagnosis is the hard part. Treatment is straightforward. Most patients improve within weeks once someone finally gets the diagnosis right. PERT: Enzyme replacement capsules with every meal and snack. Lipase, protease, amylase in one capsule. Stool quality improves within 2 to 4 weeks at the right dose. Bloating drops. Weight starts coming back. Most patients say they wish someone had started this a year ago. Dosing: 40,000 to 50,000 units lipase per main meal. 25,000 per snack. Symptoms don’t improve? Increase the dose. Not switch medications. Not stop PERT. Increase. Most patients we see are underdosed because nobody titrated properly after the initial prescription. Diet: Old textbooks said cut fat. Wrong approach for a malnourished patient. Current practice is normalise fat intake, adjust PERT dose to match, because restricting calories in someone already losing weight from months of malabsorption makes the problem worse not better. Monitoring: Check fat-soluble vitamins. Supplement what’s low. Track weight monthly. Repeat fecal elastase. And manage the underlying cause, pancreatitis, cancer, surgical, alongside the enzyme replacement rather than running two separate treatment tracks in two separate clinics that don’t talk to each other. Treatment works. Getting to the diagnosis is where most patients lose time. Read more on metabolic connections to understand how pancreatic dysfunction ties into broader metabolic problems that need managing together rather than in isolation. Why Choose Dr. Vipulroy Rathod for Pancreatic Enzyme Deficiency? Dr. Vipulroy Rathod has spent over 30 years managing pancreatic disease at Fortis Hospital Mulund. Diagnosed exocrine insufficiency in patients labelled IBS for years. EUS since 1998, underlying cause identified alongside the enzyme deficiency every time. 35 countries worth of physicians trained in this approach. Patients arrive malnourished, frustrated, undiagnosed. Most leave with enzyme replacement at the right dose, a clear explanation for symptoms nobody else investigated, and a plan that actually addresses both the deficiency and whatever caused it.   Book your consultation today with one of India’s most experienced specialists for pancreatic enzyme deficiency diagnosis and management. Book Appointment Call now Frequently Asked Questions What causes pancreatic enzyme deficiency? Chronic pancreatitis is the most common cause, followed by pancreatic cancer, cystic fibrosis, and pancreatic surgery that removes enzyme-producing tissue. How is pancreatic enzyme deficiency diagnosed? Fecal elastase test is the most common non-invasive method, with levels below 200 indicating moderate deficiency and below 100 indicating severe. Can pancreatic enzyme deficiency be cured? The underlying cause determines whether it’s reversible, but most cases require lifelong enzyme replacement therapy to manage symptoms and prevent malnutrition. What happens if pancreatic enzyme deficiency is left untreated? Untreated EPI leads to progressive malnutrition, fat-soluble vitamin deficiencies, osteoporosis, weight loss, and significantly reduced quality of life. Reference links- Exocrine Pancreatic Insufficiency Guidelines — American College of Gastroenterology Pancreatic Enzyme Replacement Therapy — World Gastroenterology Organisation

Endoscopic ultrasound puts a high-frequency ultrasound probe on the tip of a flexible endoscope and images organs from inside the GI tract, millimetres from the target rather than through layers of skin and fat from outside. It’s needed when CT or MRI can’t give a clear answer, when deep tissue biopsy is required without surgery, or when cancer staging depends on detail external imaging consistently misses. We use it because it sees what other scans don’t, and in pancreatic, biliary, and upper GI disease that difference changes treatment decisions regularly. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “EUS is the investigation that closes the gap between what CT shows and what’s actually there, and in pancreatic, oesophageal, and gastric disease that gap is often the difference between the right treatment plan and the wrong one.” What Is EUS and How Does It Work? Standard endoscopy looks at the surface. EUS looks through the wall and beyond. Not a small difference when you need to know what’s happening in the pancreas or inside a lymph node CT flagged but couldn’t characterise. Mechanism: Ultrasound transducer on the scope tip, positioned inside the stomach or duodenum, images wall layers, lymph nodes, vessels, and adjacent organs at 5 to 12 MHz frequencies, resolution that shows individual tissue layers CT physically cannot distinguish from the outside. Biopsy: Needle passes through the GI wall into a pancreatic mass, lymph node, or submucosal lesion under real-time ultrasound guidance, no external incision, tissue result often changes the entire treatment plan because imaging alone can suggest but biopsy confirms. Procedure: Sedation, scope through the mouth into stomach or duodenum for upper EUS, through rectum for rectal staging, 30 to 60 minutes total, home same day, and most patients are surprised it was less involved than they expected going in. Safety: Complication rate under 1% for diagnostic EUS, 1 to 2% for FNA, serious events like perforation are rare when someone experienced is doing it, and the information gained almost always outweighs the small procedural risk in patients where EUS is genuinely indicated. EUS delivers information no other single investigation provides in one session. Specialist in endoscopic ultrasound uses it as the primary tool for conditions where it genuinely changes what happens next. When Is EUS Actually Needed? Not for every GI complaint. Specific decision points where its accuracy changes the management plan. Outside those, it’s not the right investigation. Pancreatic: Any pancreatic mass, cyst, or suspected cancer needs EUS because CT misses sub-2 cm tumours routinely, and if you’ve had persistent upper abdominal symptoms with a normal CT that doesn’t explain them, EUS is where the answer usually sits rather than another round of the same scan. Staging: Confirmed oesophageal, gastric, pancreatic, or rectal cancer needs EUS for T and N staging because tumour depth and nodal involvement measured on EUS consistently outperform CT, and getting the stage wrong means the patient ends up on a treatment pathway that doesn’t match their actual disease. Submucosal: Lumps found underneath the surface on routine endoscopy, GISTs, leiomyomas, carcinoid tumours, need EUS to characterise layer of origin, size, and internal features before anyone decides whether to remove or watch, and standard endoscopy alone cannot make that call. Biliary: Bile duct stones missed on ultrasound, suspected bile duct cancer, ampullary tumours, all evaluated more accurately on EUS than external imaging, and EUS-guided FNA of bile duct masses gives tissue diagnosis that ERCP brushings miss in a meaningful proportion of cases. EUS earns its place when the answer genuinely matters for treatment. Read more on EUS in pancreatic cancer to see how it changes diagnosis and staging decisions specifically in pancreatic disease. Why Choose Dr. Vipulroy Rathod for Endoscopic Ultrasound? Dr. Vipulroy Rathod has been performing diagnostic and therapeutic EUS since 1998 at Fortis Hospital Mulund. Over 30 years of case volume across pancreatic, biliary, oesophageal, gastric, and rectal EUS. First Indian to receive the FASGE fellowship. 35 countries worth of physicians trained in EUS technique and clinical interpretation. Patients arrive with inconclusive CT reports and months of unanswered questions. Most leave with a finding, a tissue diagnosis, and a clear next step nobody else had been able to provide.   Book your consultation today with one of India’s most experienced EUS specialists for accurate diagnosis and intervention. Book Appointment Call now Frequently Asked Questions What is the difference between EUS and regular endoscopy? Regular endoscopy sees the surface lining while EUS images through the wall and surrounding structures using ultrasound for deeper diagnostic detail. Is EUS painful? EUS is performed under sedation and most patients experience minimal discomfort during and after the procedure. Can EUS detect cancer that CT missed? Yes, EUS detects pancreatic and GI tract lesions under 2 cm that CT regularly misses and provides tissue biopsy in the same session. How long does an EUS procedure take? EUS with or without biopsy typically takes 30 to 60 minutes including sedation and recovery time. Reference links- Endoscopic Ultrasound Indications and Guidelines — American Society for Gastrointestinal Endoscopy EUS in GI Disease Diagnosis — World Gastroenterology Organisation

Pancreatic cancer risk factors include smoking, long-standing diabetes, obesity, chronic pancreatitis, family history, certain gene mutations like BRCA2 and PALB2, these are the big ones. Most patients we diagnose carried two or three of these for years and nobody put them together into a risk picture that warranted investigation. That gap between having identifiable risk factors and someone actually acting on them is where most late diagnoses come from. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Most patients diagnosed with pancreatic cancer had at least two identifiable risk factors that nobody connected together early enough to trigger proper investigation, and that pattern repeats itself in clinical practice far more often than it should.” What Are the Major Risk Factors for Pancreatic Cancer? Some you can change. Some you can’t. But knowing what you carry changes how seriously vague symptoms should be taken when they show up. Smoking: Doubles lifetime risk, roughly. About 25% of all pancreatic cancers trace back to this. Even after quitting the risk stays elevated for 10 to 15 years before it starts coming down, so if you smoked for 20 years and quit 5 years ago and now you have persistent upper abdominal pain, you’re not in the same category as someone who never touched a cigarette. Diabetes: Two different stories here. Long-standing Type 2 carries elevated risk through years of insulin resistance. But new onset diabetes after 50 in someone who isn’t overweight and has no metabolic reason for it, that’s a red flag most doctors miss because they start metformin and move on without ever imaging the pancreas to check what’s actually going on underneath. Obesity: BMI above 30 bumps up risk by 20 to 30%. Visceral fat drives the link through inflammatory mediators that damage tissue over time. Stack central obesity with diabetes and smoking in the same patient and you’ve got a compounded risk profile that nobody mentions during a routine check-up because nobody is thinking about the pancreas. Pancreatitis: Chronic pancreatitis raises lifetime risk 8 to 10 fold. Hereditary pancreatitis goes higher still. Problem is, pancreatitis pain and early pancreatic cancer pain feel identical to the patient, so the cancer hides inside a condition that already explains the symptoms. These rarely exist alone. Most patients carry two or three. A pancreatic cancer treatment specialist maps the full profile and decides investigation thresholds from there. What About Genetic and Family Risk? Not all pancreatic cancer is random. Around 10% have a hereditary component and these families need a completely different approach to surveillance. Family: One first-degree relative with pancreatic cancer, roughly double your risk. Two or more, 6 to 12 times baseline. These patients should be on annual EUS from age 50 or 10 years before the youngest family diagnosis, whichever hits first, and most of them have never been told this. BRCA2: 3 to 10 fold elevated risk depending on family history. Structured EUS surveillance catches small lesions before they produce symptoms. If you know you carry BRCA2 and nobody has mentioned pancreatic screening, that’s a conversation you need to start yourself because it won’t come to you automatically. PALB2: Less talked about than BRCA2 but the pancreatic cancer risk is comparable. Same surveillance category, same annual EUS, same urgency. Most PALB2 carriers have no idea pancreatic screening should even be on their radar. Lynch: Mismatch repair gene mutations. Usually these patients are already in surveillance for colorectal and endometrial cancer. Adding pancreatic screening to the same programme makes clinical sense. Rarely happens in practice though. Genetic risk changes when surveillance starts and how aggressive it should be. Read more on detection to understand why finding this cancer before symptoms develop is the only approach that consistently changes what happens next for high-risk patients. Why choose Dr. Vipulroy Rathod to identify and avoid pancreatic cancer risk factors ? Dr. Vipulroy Rathod has spent over 30 years at Fortis Hospital Mulund managing pancreatic disease through EUS, fine needle aspiration, and structured high-risk surveillance. Risk factors sitting unconnected in patient records for years, finally mapped into a proper surveillance plan. Small lesions found in patients whose prior workups had missed the pancreas entirely. 35 countries worth of physicians trained in this specific approach. Most patients walk in having never been told their combination of risk factors warranted active screening. Many walk out with a programme that actually watches for this cancer before it decides to announce itself. 📞 Call Now: +91 9820091763 Book your consultation today with one of India’s most experienced specialists for identifying risk factors and avoid pancreatic cancer. Book Appointment Call now Frequently Asked Questions Does smoking increase pancreatic cancer risk? Yes, smoking roughly doubles lifetime pancreatic cancer risk and accounts for approximately 25% of all cases. Can diabetes be an early sign of pancreatic cancer? New onset diabetes after 50 in a non-obese patient with no metabolic risk factors can be an early signal of underlying pancreatic cancer. Who should get screened for pancreatic cancer? BRCA2 and PALB2 carriers, patients with familial pancreatic cancer, hereditary pancreatitis, and Lynch syndrome benefit most from structured EUS surveillance. Does chronic pancreatitis increase pancreatic cancer risk? Yes, chronic pancreatitis increases lifetime pancreatic cancer risk 8 to 10 fold and hereditary pancreatitis raises it even further. Reference links- Pancreatic Cancer Risk Factor Guidelines — American Society for Gastrointestinal Endoscopy Hereditary Pancreatic Cancer Surveillance — World Gastroenterology Organisation

Pancreatic cancer is difficult to detect early because the pancreas is located deep in the abdomen, preventing small, early-stage tumours from being felt during exams or easily seen on imaging. Additionally, symptoms are vague, such as indigestion or mild back pain, mimicking other conditions, and often do not appear until the tumour has grown or spread. By the time most patients receive a diagnosis, the cancer has already moved past the stage where surgical cure was still a realistic option. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Pancreatic cancer hides because of its anatomy and because its early signals are exactly the kind nobody investigates aggressively until something dramatic forces the issue, which is usually too late to change the outcome.” Why Does This Cancer Stay Hidden So Long? Not one reason. Several, all working together, and the combination is what makes pancreatic cancer different from most other GI cancers. Anatomy: Pancreas tucked behind the stomach, surrounded by bowel loops and fat, ultrasound barely reaches it properly and CT misses tumours under 2 cm more often than most patients or their doctors realise. Symptoms: Upper abdominal discomfort, mild back pain, appetite dropping off, slow weight loss. Every single one of these gets blamed on something else, acidity, gastritis, work stress, ageing, for months before anyone even considers the pancreas. Diabetes: New diabetes after 50 in someone who isn’t overweight and has no metabolic history. That’s a red flag. But most doctors start metformin and move on without ever ordering a pancreatic scan, and the tumour keeps growing while the blood sugar gets managed as a standalone problem. No Screening: Colonoscopy catches colorectal cancer early. Mammography catches breast cancer early. Pancreatic cancer has nothing equivalent, so unless a patient is already in a high-risk surveillance programme, nobody is looking until symptoms force the conversation. These factors reinforce each other in ways that keep pushing diagnosis later, and specialist in pancreatic cancer treatment uses EUS whenever clinical suspicion exists rather than waiting for CT to eventually declare something that should have been found months earlier. How Do You Actually Catch It Early? Right investigation. Right patient. Right timing. Not hoping the next scan shows what the last one missed. EUS: Imaging probe positioned millimetres from the pancreas through the stomach wall. Picks up sub-2 cm tumours CT misses. Biopsy in the same session. This is the most effective early detection tool available and the reason patients with inconclusive CT findings should be moving toward EUS, not repeating the same scan again. Surveillance: BRCA2 carriers, first-degree relatives of pancreatic cancer patients, hereditary pancreatitis. All need annual EUS. Finding a small lesion before symptoms develop is the only proven way to catch this cancer at genuinely curable stage in people with genetic predisposition. Symptom Clusters: Persistent upper abdominal pain plus unexplained weight loss. New diabetes after 50 plus painless jaundice. Any combination of these in the same patient over a short period warrants EUS, not another round of acid suppression and a follow-up appointment in six weeks. Next Step: CT inconclusive or symptoms persisting despite normal scans. EUS should be the immediate next investigation. Not a repeat CT in three months. Three months of pancreatic cancer growth is exactly the kind of delay that changes a resectable tumour into an unresectable one. Catching pancreatic cancer early requires the right tool at the right decision point, not luck. Read more on warning signs to understand which specific signals deserve aggressive investigation and which patient profiles need a much lower threshold for imaging than the general population. Why choose Dr. Vipulroy Rathod to detect pancreatic cancer ? Dr. Vipulroy Rathod has spent over 30 years catching pancreatic cancer through EUS, fine needle aspiration, and structured high-risk surveillance at Fortis Hospital Mulund. Small resectable tumours in patients whose CT scans had been called normal. Diagnoses made where other pathways had stopped looking. Physicians from 35 countries trained in this specific approach. Most patients arrive after months of reassurance that nothing was wrong, and many leave with a real diagnosis caught early enough to actually treat. That gap between reassurance and reality is exactly what proper investigation closes. 📞 Call Now: +91 9820091763 Book your consultation today with one of India’s most experienced specialists for detecting pancreatic cancer. Book Appointment Call now Frequently Asked Questions Why does pancreatic cancer get diagnosed so late? The pancreas sits deep in the abdomen, early symptoms are vague, and no routine screening exists outside high-risk patient groups. Can pancreatic cancer be detected before symptoms develop? Yes, EUS surveillance can find small pancreatic lesions in high-risk patients before any symptoms appear. Is CT scan enough to detect pancreatic cancer early? No, CT often misses pancreatic tumours under 2 cm and EUS is required for accurate early detection in most cases. Who should get EUS surveillance for pancreatic cancer? BRCA2 carriers, patients with familial pancreatic cancer, and those with hereditary pancreatitis benefit most from annual EUS surveillance. Reference links- Pancreatic Cancer Early Detection Challenges — American Society for Gastrointestinal Endoscopy Pancreatic Cancer Surveillance Guidelines — World Gastroenterology Organisation

EUS is the most accurate single tool we have for diagnosing pancreatic cancer because the imaging probe sits within millimetres of the pancreas, picking up tumours under 2 cm that CT and MRI miss while letting us biopsy the same lesion in the same session. It changed pancreatic cancer diagnosis fundamentally because external scans on their own simply cannot deliver the kind of detail or tissue sampling early-stage decisions actually depend on. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “EUS is not just another imaging option in pancreatic cancer, it is often the difference between catching a small resectable tumour and finding the same disease six months later when the window for cure has already closed.” What Role Does EUS Play in Pancreatic Cancer Diagnosis? EUS does several things in one session that no other modality can deliver together, which is exactly why it sits at the centre of how pancreatic cancer actually gets diagnosed in practice. Detection: EUS picks up pancreatic lesions under 2 cm with sensitivity that consistently beats CT and MRI for small tumours, finding disease at the stage where surgical resection still offers a real chance of cure rather than catching it months later when the options have already started narrowing. Biopsy: EUS-guided fine needle aspiration samples the tumour directly through the stomach or duodenal wall in the same session as imaging, which matters because pancreatic cancer treatment is far too aggressive to start without proper biopsy proof and external scans can only suggest rather than confirm what’s there. Cysts: EUS evaluates pancreatic cystic lesions and tells benign serous cysts apart from premalignant mucinous cysts and IPMNs through fluid sampling and morphology assessment, picking up subtle features CT cannot show and changing surveillance decisions in a meaningful percentage of patients. Vessels: EUS shows the relationship between tumour and major vessels with millimetre accuracy that decides surgical resectability, which is why patients who looked unresectable on CT sometimes turn out to be operable after EUS clarifies what’s actually happening at the vascular interface. EUS gives information no external scan can replicate, and specialist in endoscopic ultrasound treats it as the primary diagnostic tool rather than an optional add-on after CT and MRI have already finished guessing. When Should EUS Be Used in the Pancreatic Cancer Workup? EUS belongs in the workup at specific decision points where its accuracy genuinely changes the management plan, not as a routine box-tick for every patient walking through the door. Suspicion: Patients with worrying symptoms and inconclusive CT or MRI findings need EUS to either confirm or rule out pancreatic disease, because vague upper abdominal pain alongside a normal external scan still leaves the question wide open and the only way to close it properly is direct visualisation. Cysts: Any pancreatic cyst found incidentally on CT or MRI deserves EUS evaluation to characterise it accurately, because surveillance decisions hinge on cyst type and external scans cannot reliably tell the benign cysts from the ones with real malignant potential underneath. Staging: Confirmed pancreatic cancer needs EUS-based staging alongside CT and MRI because tumour size, vascular involvement, and nodal disease all get measured more accurately on EUS, which directly affects whether surgery, neoadjuvant chemotherapy, or palliative care becomes the right pathway. High Risk: BRCA2 carriers, patients with familial pancreatic cancer history, and those with hereditary pancreatitis benefit from annual EUS surveillance because finding small lesions before symptoms develop is the only realistic way to catch this cancer at curable stage in genetically predisposed patients. EUS earns its place in pancreatic cancer workup at every point where the answer actually matters for treatment. Read more on neurolysis to see how the same EUS technology delivers therapeutic intervention beyond just diagnosis when disease is already advanced. Why choose Dr. Vipulroy Rathod to understand the role of EUS in diagnosis of pancreatic cancer ? Dr. Vipulroy Rathod has spent over 30 years performing diagnostic and therapeutic EUS in pancreatic disease at Fortis Hospital Mulund, finding small resectable tumours that external scans had labelled normal and providing tissue diagnosis that changed the entire treatment plan for patients whose CT findings stayed inconclusive, and has trained physicians from 35 countries in this exact diagnostic pathway. Most patients arrive having been told something pancreatic was uncertain on CT, and many leave with a clear answer based on EUS imaging and biopsy that either confirmed cancer at a stage where treatment still works or ruled it out properly so the search could continue elsewhere instead of getting stuck in repeat scans that never settle the question. 📞 Call Now: +91 9820091763 Book your consultation today with one of India’s most experienced specialists for understanding EUS diagnosis for pancreatic cancer  Book Appointment Call now Frequently Asked Questions Is EUS more accurate than CT for pancreatic cancer diagnosis? Yes, EUS detects pancreatic tumours under 2 cm and provides tissue biopsy in the same session, outperforming CT for small lesion detection. Can EUS confirm pancreatic cancer diagnosis? Yes, EUS-guided fine needle aspiration provides histological tissue confirmation that is essential before starting any pancreatic cancer treatment. Is EUS painful for pancreatic cancer evaluation? EUS is performed under sedation and patients typically experience minimal discomfort during and after the procedure. How long does an EUS procedure for pancreatic cancer take? EUS with fine needle biopsy for pancreatic cancer typically takes 30 to 60 minutes including sedation and recovery time. Reference links- EUS in Pancreatic Cancer Diagnosis — American Society for Gastrointestinal Endoscopy Pancreatic Cancer EUS Guidelines — World Gastroenterology Organisation

Pancreatic cancer staging uses the TNM system, looking at the tumour itself, whether nearby lymph nodes are involved, and whether disease has reached distant organs, with the resulting stages from I through IV deciding what treatment is realistically possible. EUS combined with CT and MRI gives the most accurate staging picture because external scans alone consistently miss small tumours and the kind of subtle nodal involvement that quietly changes the entire treatment plan. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Staging accuracy in pancreatic cancer is everything because the difference between Stage I resectable disease and Stage III locally advanced disease often comes down to a few millimetres of vascular involvement that CT cannot reliably show, and getting that wrong sends the patient down completely the wrong treatment pathway.” How Is Pancreatic Cancer Staged Using the TNM System? TNM works by combining three measurements into a single picture, and that combined picture decides what’s realistically possible for the patient sitting in front of you. Tumour: T staging looks at size and local invasion with T1 meaning a tumour under 2 cm sitting inside the pancreas while T4 means disease has reached major vessels like the celiac axis or superior mesenteric artery, so the difference between T2 and T4 often decides surgical eligibility even when the actual size on imaging looks similar across the two stages. Nodes: N staging counts how many regional lymph nodes contain cancer with N0 meaning none, N1 meaning 1 to 3 positive, and N2 meaning 4 or more, and EUS-guided FNA biopsy of suspicious nodes gives the kind of accuracy CT-based staging consistently fails to deliver here because size alone never confirms whether a node is actually involved. Metastasis: M staging is binary because either disease has reached distant organs or it hasn’t, but even one small liver lesion or peritoneal deposit moves the patient straight to Stage IV regardless of how favourable the primary tumour and nodes might look in isolation, which is why thorough M assessment matters as much as anything else in the workup. Stages: Stage I means localised and resectable, Stage II means nearby tissue spread but still potentially operable, Stage III means locally advanced with vascular involvement that often closes the surgical door, while Stage IV means metastatic disease where surgery is almost never the answer anyway and management shifts toward systemic treatment. Getting all three components measured accurately at the start changes the entire treatment plan, and specialist in pancreatic cancer treatment uses EUS alongside CT and MRI rather than relying on external imaging that consistently misses what matters. Why Does EUS Matter So Much in Pancreatic Cancer Staging? CT and MRI give the broad anatomical picture, but EUS gets close enough to the tumour to see what those scans miss, and that proximity changes staging decisions in a meaningful percentage of cases. Size: EUS picks up pancreatic tumours under 2 cm that CT regularly misses entirely because the smallest resectable cancers carry the best survival rates and finding them through EUS is often the only way these patients reach surgical consultation while early-stage intervention is still possible. Vessels: Vascular involvement is the single biggest factor in surgical resectability and EUS shows the relationship between tumour and major vessels with millimetre accuracy CT simply cannot replicate, which is why patients who looked unresectable on CT sometimes turn out to be operable after proper EUS staging changes the picture. Nodes: EUS-guided FNA samples suspicious lymph nodes that CT only flags by size, giving real tissue diagnosis rather than radiological guess, and that distinction matters enormously because not every enlarged node is malignant and not every normal-sized node is clean even when the scan looks reassuring at first glance. Tissue: EUS allows fine needle biopsy of the primary tumour itself in the same session as staging providing histological confirmation before any treatment decision gets made, which is critical because pancreatic cancer treatment is too aggressive to start without biopsy proof sitting in the file ready to act on. EUS-based staging consistently changes surgical decisions in patients whose CT staging looked definitive in either direction. Read more on staging to see how staging principles apply across all GI cancers and why the staging investigation drives the treatment plan rather than the other way around. Why choose Dr. Vipulroy Rathod for analyzing the early staging of pancreatic cancer ? Dr. Vipulroy Rathod has spent over 30 years staging pancreatic cancer through EUS, FNA biopsy, and integrated imaging at Fortis Hospital Mulund, catching the small resectable tumours that CT staging missed entirely and clarifying borderline cases where vascular involvement decided whether the patient was operable, and has trained physicians from 35 countries in this specific staging approach. Most patients arrive with a CT staging report and an assumption their disease is one stage when in fact it’s another, and many leave with EUS-corrected staging that opened up surgical options nobody thought were on the table or, equally importantly, ruled out unnecessary surgery in cases where the disease was already further along than CT suggested it was. 📞 Call Now: +91 9820091763 Book your consultation today with one of India’s most experienced specialists for understanding the stages of pancreatic cancer Book Appointment Call now Frequently Asked Questions What is the most accurate staging method for pancreatic cancer? EUS combined with CT and MRI provides the most accurate pancreatic cancer staging, particularly for tumour size, vascular involvement, and nodal disease. Can pancreatic cancer staging change after treatment starts? Yes, restaging is standard practice after neoadjuvant chemotherapy or radiation to assess response and reconsider surgical resectability. What stage of pancreatic cancer is operable? Stage I and II pancreatic cancers are typically resectable, while Stage III locally advanced disease may become resectable after neoadjuvant therapy. Does Stage IV pancreatic cancer mean surgery is not possible? Yes, Stage IV pancreatic cancer with distant metastasis is rarely treated with surgery, and management focuses on systemic chemotherapy and palliative intervention. Reference links- Pancreatic Cancer Staging Guidelines — American Society for

Pancreatic cancer rarely announces itself early because the pancreas sits buried deep behind the stomach and produces almost nothing in the way of obvious symptoms until the disease has already moved past easy treatment, but there are signals worth taking seriously, and they tend to show up as unexplained weight loss, persistent upper abdominal or back pain, new diabetes after 50 with no real reason, painless jaundice, oily stools, and a slow loss of appetite that doesn’t sort itself out. Most patients land at advanced stage simply because nobody connected those signals back to the pancreas in time to do anything useful about them. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Pancreatic cancer is one of those conditions where the difference between early and late diagnosis is often the difference between treatable disease and palliative care, and most patients arrive late because the early signs are exactly the kind that get attributed to acidity, stress, or age before anyone thinks to investigate properly.” What Are the Early Warning Signs of Pancreatic Cancer? Individually each of these can mean nothing, but when two or three cluster together or run on for weeks without explanation, they start telling a different story. Weight: Losing 4 to 5 kg without changing anything about your eating or activity is one of the most consistent early signals because pancreatic enzyme production gets disrupted long before any other symptom appears, so the body slowly stops absorbing nutrients properly while the patient and their doctor assume it’s just stress or work catching up. Pain: That dull ache in the upper abdomen radiating through to the back, worse after meals or at night, is a classic pancreatic pattern, and patients often spend months getting treated for gastritis or muscle strain before someone finally connects the pain to the actual organ producing it behind the stomach. Diabetes: New diabetes in a non-obese patient over 50 with no metabolic explanation is a recognised early signal because the tumour disrupts insulin-producing tissue, yet most of these cases get filed straight under endocrine disease and the pancreas itself never gets imaged properly. Jaundice: Yellowing of skin and eyes without any cramping pain shows up when a tumour in the head of the pancreas blocks the bile duct, and unlike gallstone jaundice it tends to arrive quietly without the dramatic abdominal pain, which is exactly why patients delay coming in until family members notice the colour change at home. These signals get more serious when two or more cluster together in the same patient over a short window, and a pancreatic cancer treatment specialist investigates that combination properly rather than treating each symptom as a standalone problem. When Should These Signs Trigger Proper Investigation? Not every symptom on this list means cancer, but specific patient profiles need a much lower threshold for investigation than the general population. Family: Patients with a first-degree relative diagnosed with pancreatic cancer carry significantly elevated lifetime risk and should already be on EUS surveillance regardless of symptoms, because finding a small lesion before any signal develops is the entire point of surveillance and waiting for warning signs in this group means waiting too long. BRCA2: Confirmed BRCA2, BRCA1, or PALB2 carriers face meaningfully higher pancreatic cancer risk and benefit from annual EUS surveillance from age 50, and any of the warning signs in this group should trigger imaging within days rather than the wait-and-see approach used for the same symptoms in average-risk patients. Pancreatitis: Patients living with chronic pancreatitis carry elevated background cancer risk and warning signs can easily get attributed to the pancreatitis itself, so any change in pain pattern, new weight loss, or onset of diabetes in this group needs proper EUS investigation rather than dismissal as the underlying disease acting up. Smokers: Long-term smokers carry roughly double the pancreatic cancer risk of non-smokers and warning signs are statistically more likely to actually mean something here, which is why a smoker over 50 with persistent upper abdominal symptoms genuinely deserves proper investigation rather than the standard reassurance most of them get sent home with. A small lesion found early can be treated, while the same disease six months later usually cannot, and that gap is exactly what surveillance and proper investigation are designed to close. Read more on EUS detection to see which symptoms map to which findings on EUS and why the timing of investigation makes such a real difference. Why choose Dr. Vipulroy Rathod for screening early warning signs of pancreatic cancer ? Dr. Vipulroy Rathod has spent over 30 years investigating pancreatic disease through EUS, fine needle aspiration biopsy, and metabolic workup at Fortis Hospital Mulund, finding small pancreatic lesions in patients whose CT scans were called normal and whose symptoms were being managed as something else entirely, and has trained physicians from 35 countries in this exact diagnostic pathway. Most patients arrive having been reassured for months that nothing serious was happening, and many leave with a real diagnosis caught early enough to actually do something about it, which is the entire reason proper investigation matters at this point in the disease course. 📞 Call Now: +91 9820091763 Book your consultation today with one of India’s most experienced specialists for hepatitis and liver cancer evaluation. Book Appointment Call now Frequently Asked Questions What is the most common first symptom of pancreatic cancer? Unexplained weight loss combined with vague upper abdominal discomfort is the most common early presentation of pancreatic cancer. Can pancreatic cancer be detected before symptoms start? Yes, EUS surveillance can find small pancreatic lesions in high-risk patients before any symptoms develop. Is new onset diabetes a sign of pancreatic cancer? New diabetes in a non-obese patient over 50 with no metabolic risk factors is a recognised early signal that warrants pancreatic imaging. How is pancreatic cancer diagnosed early? EUS combined with fine needle aspiration biopsy is the most accurate method for early pancreatic cancer detection in symptomatic and high-risk patients. Reference links- Pancreatic Cancer Early Detection Guidelines — American

Chronic hepatitis B and hepatitis C are the two biggest infectious causes of liver cancer worldwide, with each virus driving cancer risk through a different mechanism. Hepatitis B can trigger cancer directly by embedding into liver cell DNA even without cirrhosis, while hepatitis C typically raises risk through the cirrhosis pathway where years of inflammation build scarring that eventually sets the stage for malignancy. According to Dr. Vipulroy Rathod, an experienced Gastroenterologist in Mumbai, “The connection between hepatitis and liver cancer is one of the most well-established links in all of medicine, and yet patients with chronic hepatitis still slip through without being told they need regular screening until a tumour shows up and suddenly the conversation shifts from prevention to damage control.” How does hepatitis actually cause liver cancer? Both viruses jack up cancer risk but they get there through completely different back roads which is why you can’t just run the same surveillance playbook for both, and understanding which mechanism is chewing through a particular patient’s liver changes how hard they need watching and what specifically the screening is looking for. Hep B — direct sabotage: This virus doesn’t bother waiting for cirrhosis to roll in before it starts causing problems because it buries itself directly into the DNA of liver cells and can flip the switches that turn a normal cell cancerous from the inside out, which is why hep B patients can grow hepatocellular carcinoma in a liver that looks perfectly clean on every other test and has zero scarring anywhere. Hep C — the long grind: Hep C takes the scenic route to cancer by keeping the liver in a state of constant low-grade warfare where inflammation slowly stacks fibrosis on top of fibrosis over decades until cirrhosis sets in and that wrecked cirrhotic environment is what eventually rolls out the red carpet for cancer to take root. Cell turnover gone wrong: Both viruses force liver cells to die and regenerate faster than they normally would, and that sped-up turnover is basically a lottery where every cell division carries a small chance of a genetic screw-up and the more tickets you buy over decades of chronic infection the higher the odds that one of those screw-ups eventually becomes a cancer. Stacking damage: Patients carrying both viruses at once or either virus paired with years of heavy booze face cancer risk that doesn’t just climb it rockets, because each factor dumps its own damage on top of what the other’s already done and the liver is copping hits from multiple directions with no breathing room to recover between rounds. If chronic hepatitis has already been diagnosed and you want the full picture of what screening and treatment look like, our liver cancer treatment page covers everything from surveillance schedules through intervention options depending on what shows up. Can treating the virus actually bring the cancer risk down? Treating hepatitis absolutely bends the curve but how much risk drops depends heavily on when treatment happens relative to how much damage the liver has already copped, which is why getting treated at the fibrosis stage versus the cirrhosis stage can mean the difference between a patient who mostly dodges cancer risk and one who carries it around for the rest of their life. Hep B antivirals: Squashing the virus with long-term antivirals drops cancer risk dramatically but doesn’t wipe it out completely because the viral DNA that’s already welded itself into liver cell chromosomes stays parked there even when blood tests show the virus as undetectable, meaning hep B patients on treatment still need six-monthly screening because that embedded DNA can still cause havoc years after the virus itself went quiet. Hep C cure: Direct-acting antivirals now knock out hep C in over 95 percent of patients and clearing the virus chops the cancer risk significantly, but patients who already had cirrhosis before getting cured still sit on elevated risk for years afterward because the scarred-up liver environment that cancer loves doesn’t just pack up and leave the moment the virus gets evicted. Earlier is always better: A patient who gets treated before fibrosis digs in has a wildly better long-term outlook than one who gets treated after cirrhosis has already cemented itself, which is the single strongest argument for catching hepatitis early and treating immediately rather than the outdated approach of sitting on your hands and waiting for the liver to start visibly struggling before doing anything. Screening never fully stops: Even patients with undetectable viral loads and successful treatment still need continued surveillance if they had significant fibrosis or cirrhosis when they started therapy, because cancer risk takes years to properly come down and yanking screening away too early is exactly how tumours get missed in people who assumed the worst was behind them. Knowing how the two hepatitis types differ at a fundamental level helps guide which screening approach fits, and our hepatitis B vs hepatitis C blog breaks down the key differences between the two viruses and why the surveillance game plan can’t just be photocopied from one to the other. Why choose Dr. Vipulroy Rathod for hepatitis and liver cancer screening? Dr. Vipulroy Rathod has over 30 years in gastroenterology and hepatology with more than 80,000 endoscopic procedures behind him, and hepatitis-related cancer risk is one of those areas where knowing whether the patient needs watching because of viral DNA buried inside liver cells or because of a cirrhotic landscape that cancer thrives in changes the entire surveillance setup, and a gastroenterologist who treats both situations as identical is missing a distinction that directly affects how often imaging happens and what it’s actually hunting for. What patients get here is hepatitis management that doesn’t just treat the virus and dust its hands off but keeps the cancer surveillance running for as long as the risk stays elevated, because clearing the bug or beating it down with antivirals is only half the job and the other half is making sure the liver doesn’t